Last reviewed · How we verify
11C-PBR28
11C-PBR28, developed by Columbia University, is a marketed small molecule with an unknown target, currently lacking a defined primary indication or revenue data. Its key strength lies in its unique mechanism of action, which may offer therapeutic benefits not yet fully explored. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition.
At a glance
| Generic name | 11C-PBR28 |
|---|---|
| Also known as | Non-proprietary, 11C-[O-methyl-11C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Brain Inflammation and Function in Alcoholism (EARLY_PHASE1)
- Evaluating the Role of Neuroinflammation in Low Back Pain (PHASE2)
- TSPO Occupancy in the Human Lung (NA)
- Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation (PHASE4)
- Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients (PHASE2)
- Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR
- SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (PHASE1,PHASE2)
- CBD-Microglia PET Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 11C-PBR28 CI brief — competitive landscape report
- 11C-PBR28 updates RSS · CI watch RSS
- Columbia University portfolio CI